Abstract
Evidence is accumulating to suggest that Chlamydia pneumoniae may have a role in the development and/or progression of atherosclerotic-related disorders, in particular coronary heart disease (CHD). The evidence for C. pneumoniae as a potential causative agent is largely based on the findings of (1) seroepidemiological studies, (2) examination of atheromatous plaque specimens, (3) in vitro experiments and animal models and, recently, (4) preliminary anti-chlamydial antibiotic intervention studies. This chapter aims at focusing on the potential, and intriguing, role of antimicrobial therapy in the secondary prevention of CHD. The findings of the preliminary pilot studies are reviewed, as are the aims and controversies surrounding large-scale, prospective intervention trials, now in progress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mendall MA, Carrington D, Strachan D et al (1995) Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 30: 121–128
Saikku P, Mattila K, Nieminen MS et al (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2: 983–986
Thom DH, Grayston JT, Siscovick DS et al (1992) Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268: 68–72
Patel P, Mendall MA, Carrington D et al (1995) Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711–714
Leatham EWL, Bath PM, Tooze JA et al (1995) Increased monocyte tissue factor expression in coronary disease. Br Heart J 73: 10–13
Gupta S, Leatham EW, Carrington D et al (1997) The effect of azithromycin in post myocardial infarction patients with elevated Chlamydia pneumoniae antibody titres. J Am Coll Cardiol 755: 209 (abstract)
Gupta S, Leatham EW, Carrington D et al (1997) Elevated Chlamydia penumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 96: 404–407
Rizzato G, Montemurro L, Fraioli P et al (1995) Efficacy of a three day course of azithromycin in moderately severe community-acquired pnumonia. Eur Respir J 8: 398–402
Foulds G, Shepard RM, Johnson RB et al (1990) The pharmacokinetic of azithromycin in human serum and tissue. J Antimicrob Chemother 25[Suppl A]: 73–82
Black PN (1997) Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 10: 971–972
Gurfinkel E, Bozovich G, Daroca A et al (1997) Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 350: 404–407
Sinisalo J, Mattila K, Nieminen MS et al (1998) The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factor and forearm basal nitric oxide production. J Antimicrob Chemother 41: 85–92
Anderson JL, Muhlestein JB (1998) Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia. ACADEMIC study. Presented at 47th Scientific Session of American College of Cardiology Meeting, Atlanta, Georgia
Havlir DV, Dubé MP, Sattler FR et al (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 335: 392–398
Kaski JC, Chester MR, Chen L et al (1995) Rapid angiographic progression of coronary artery disease in patients with angina pectoris. Circulation 92: 2058–2065
Gupta S, Camm AJ (1997) Chlamydia pneumoniae and coronary heart disease: coincidence, association or causation? BMJ 314: 1778–1779
Gupta S, Kaski JC, Camm AJ (1998) Antibiotic therapy in coronary heart disease: hype versus hope. Br J Cardiol 5: 65–66
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Italia, Milano
About this chapter
Cite this chapter
Gupta, S., Kaski, J.C. (1999). Antibiotic Treatment in Atherosclerosis and Myocardial Infarction. In: Allegra, L., Blasi, F. (eds) Chlamydia pneumoniae. Springer, Milano. https://doi.org/10.1007/978-88-470-2280-5_20
Download citation
DOI: https://doi.org/10.1007/978-88-470-2280-5_20
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0047-6
Online ISBN: 978-88-470-2280-5
eBook Packages: Springer Book Archive